Alumis Inc.
ALMS
Rank in Stocks
#9959
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.78
Market Cap
$877.57M
Change (1 day)
1.19%
Change (1 year)
198.68%
Country
US
Trade Alumis Inc. (ALMS)
Category
Healthcare
Stock price history for Alumis Inc. (ALMS)
Highest end of day price: $2.34 on 2025-05-01
Lowest end of day price: $21.58 on 2023-05-01
Lowest end of day price: $21.58 on 2023-05-01
Stock price history of Alumis Inc. from 2023 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
